Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 12/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5981554 | 0.91 | MCL1 (0.39) | MEN1KMT2AMAPT | |
| SCHEMBL7449311 | 0.80 | MEN1 (0.33) | MEN1KMT2A | |
| SCHEMBL7455250 | 0.79 | ADAM17 (0.37) | L3MBTL1MEN1KMT2AMAPT | |
| SCHEMBL7455149 | 0.79 | TP53 (0.38) | L3MBTL1MEN1KMT2AMAPT | |
| SCHEMBL7453712 | 0.79 | TP53 (0.38) | L3MBTL1MEN1KMT2AMAPT | |
| SCHEMBL6375010 | 0.78 | MCL1 (0.39) | — | |
| SCHEMBL5996194 | 0.76 | CYP2C8 (0.40) | ESR1 | |
| SCHEMBL7455279 | 0.76 | TEAD1 (0.43) | ESR1L3MBTL1MEN1KMT2AMAPT | |
| SCHEMBL4848012 | 0.74 | ESR1 (0.39) | ESR1PTGER1 | |
| SCHEMBL7458622 | 0.73 | RORC (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7320983-B2 | α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | G.D. SEARLE LLC (US) | 2008-01-22 | — | — | US | disclosed |
| US-20070078173-A1 | Alpha- and beta-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2007-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078173-A1 | Alpha- and beta-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | DNPEP, ASPH, PREP | ESR1 1279/4885L3MBTL1 1142/4885MEN1 3710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.